Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report)’s share price was down 3.3% during mid-day trading on Wednesday . The company traded as low as $3.85 and last traded at $4.15. Approximately 42,004 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,049,645 shares. The stock had previously closed at $4.29.
Virios Therapeutics Stock Performance
The company’s 50-day moving average is $6.14 and its 200-day moving average is $3.48. The firm has a market cap of $79.92 million, a price-to-earnings ratio of -15.37 and a beta of 1.58.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Articles
- Five stocks we like better than Virios Therapeutics
- 3 Stocks to Consider Buying in October
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- What is the FTSE 100 index?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What is the NASDAQ Stock Exchange?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
